Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluation of ICP-B381 in Patients With Advanced Solid Tumors

13. november 2026 oppdatert av: Beijing InnoCare Pharma Tech Co., Ltd.

An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics, and Efficacy of ICP-B381 in Participants With Advanced Solid Tumors

To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

348

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200032
        • Rekruttering
        • Fudan University Shanghai Cancer Center
        • Ta kontakt med:
          • DingWei Ye, M.D.
          • Telefonnummer: 021-64175590*81807
          • E-post: dwyeli@163.com

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Participants must be at least 18 years old.
  2. Participants thoroughly understand study procedures, and voluntarily sign the written ICF
  3. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
  4. Expected survival time ≥3 months.
  5. Histopathologically confirmed metastatic castration-resistant prostate cancer (mCRPC) & Other advanced solid tumor
  6. Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor biopsies (for archived samples, more recently collected specimens are preferred
  7. The organ function level must meet the prescribed standards
  8. All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per CTCAE V6.0)
  9. Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug
  10. Female participant of childbearing potential must have a negative blood pregnancy test at the screening visit
  11. Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose.
  12. Participants can communicate well with the Investigator and can complete the study according to the study protocol

Exclusion Criteria:

  1. Other active malignant tumors occurred within 3 years before the first administration of the study drug
  2. Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol
  3. Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol
  4. Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other investigational anti-cancer drugs with an elution time not meeting the protocol requirements
  5. Had active bleeding within 2 months before screening or had clinically significant or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions
  6. Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration
  7. Has received systemic immunosuppressive drugs as stipulated in the protocol for 14 days before the first administration
  8. Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs
  9. Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 CYP3A before the study
  10. Has any mental or cognitive disorders that may limit their understanding, execution of the informed consent form, and compliance with the study
  11. Situations that the investigator deems unsuitable for participating in this study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: ICP-B381

ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers
Tidsramme: 2 years
2 years
The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)
Tidsramme: 2 years
2 years
Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)
Tidsramme: 2 years
2 years
Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate
Tidsramme: 2 years
2 years
Participants with other tumor types: Investigator-assessed Objective response rate (ORR)
Tidsramme: 2 years
2 years
The optimal dosing regimen for the subsequent study of ICP-B381
Tidsramme: 2 years
2 years

Sekundære resultatmål

Resultatmål
Tidsramme
Total overlevelse (OS)
Tidsramme: 2 år
2 år
Varighet av respons (DOR)
Tidsramme: 2 år
2 år
Objektiv responsrate (ORR)
Tidsramme: 2 år
2 år
Maksimal konsentrasjon (Cmax)
Tidsramme: 2 år
2 år
Disease Control Rate (DCR)
Tidsramme: 2 år
2 år
Time to Maximum Plasma Concentration (Tmax)
Tidsramme: 2 years
2 years
Half-life (T1/2)
Tidsramme: 2 years
2 years
Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)
Tidsramme: 2 years
2 years
Apparent Clearance Rate (CL/F)
Tidsramme: 2 years
2 years
Terminal Apparent Volume of Distribution (Vz/F)
Tidsramme: 2 years
2 years
Steady-state Pharmacokinetic Parameters
Tidsramme: 2 years
2 years
Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)
Tidsramme: 2 years
2 years
Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate
Tidsramme: 2 years
2 years
Participants with prostate cancer: PSA90 response rate
Tidsramme: 2 years
2 years
Participants with prostate cancer:12-week PSA response rate
Tidsramme: 2 years
2 years
Participants with prostate cancer: time to PSA progression (TTPP)
Tidsramme: 2 years
2 years
Time to First Subsequent Therapy (TFST)
Tidsramme: 2 years
2 years
Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)
Tidsramme: 2 years
2 years
Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)
Tidsramme: 2 years
2 years
Incidence rate of anti-drug antibody (ADA) against ICP-B381
Tidsramme: 2 years
2 years
Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE
Tidsramme: 2 years
2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. oktober 2026

Primær fullføring (Antatt)

1. september 2027

Studiet fullført (Antatt)

1. juli 2028

Datoer for studieregistrering

Først innsendt

22. oktober 2026

Først innsendt som oppfylte QC-kriteriene

22. oktober 2026

Først lagt ut (Faktiske)

28. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ICP-CL-01901

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere